Looking at the supply chain challenges pharmaceutical companies could face
Planning for potential disruption in 2023 will be crucial for pharmaceutical companies that wish to mitigate supply chain woes further down the line. The situation regarding COVID-19 in China is already being hailed as a potential source of supply chain disruption, with some organisations already feeling the impact – not forgetting ongoing challenges around economic instability, geopolitical risk and cybersecurity issues.
We have already witnessed much of this throughout 2022, with a surge in geopolitical disruption, labour strikes, COVID-19 disruption and supply shortages. These factors will continue to pose risks in 2023, challenging pharmaceutical companies that seek to build resilient supply chains over the course of this year and beyond.
This article outlines five of the biggest threats to pharmaceutical companies eager to realise secure supply chains in 2023.
